Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity?

Abstract

Comparing a group of infants treated with recombinant erythropoietin and iron supplementation to a group of control infants, no difference was observed concerning the transfusion need. The incidence of retinopathy of prematurity was significantly higher in the treated group. These data need to be confirmed in randomized controlled studies.